CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Human Genome Sciences, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Human Genome Sciences, Inc.
14200 Shady Grove Road
Phone: 301.309.8504p:301.309.8504 Rockville, MD  20850  United States Ticker: HGSIHGSI
This company was Merged or Acquired on 8/3/2012.
This company ceased filing statements with the SEC on 8/13/2012.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
Human Genome Sciences, Inc. (HGS) is a biopharmaceutical company. The Company’s products include BENLYSTA (belimumab) for systemic lupus erythematosus (SLE) and raxibacumab for inhalation anthrax. HGS continues to deliver raxibacumab to the United States Strategic National Stockpile (SNS) for emergency use in treating inhalation anthrax. In addition to the Company’s internal pipeline, it has financial rights to two drugs that GlaxoSmithKline (GSK) has advanced to late-stage development. These include darapladib and albiglutide. A randomized Phase 2 trial is evaluating mapatumumab in combination with Nexavar (sorafenib) for the treatment of advanced hepatocellular cancer. The Company manufactures multiple protein and antibody drugs for use in research, clinical and commercial activities. It produces and purifies these protein and antibody drugs in three process development and manufacturing facilities. In August 2012, GlaxoSmithKline plc acquired HGS.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/201212/31/2011YesYes---

Industries
SIC Code Description
2836 Biological products, except diagnostic substances
8731 Commercial physical and biological research
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, Presiding Independent Director Argeris N.Karabelas 59 10/17/2004 4/15/2002
President, Chief Executive Officer, Director DeirdreConnelly 7/30/2012 7/30/2012
Chief Financial Officer, Director AdrianRawcliffe 7/30/2012 7/30/2012
6 additional Officers and Directors records available in full report.

Business Names
Business Name
HGS France S.à r.l.
HGS Germany GmbH
HGS International S.à r.l
5 additional Business Names available in full report.

General Information
Number of Employees: 1,100 (As of 2/1/2012)
Outstanding Shares: 199,985,391 (As of 6/30/2012)
Shareholders: 578
Stock Exchange: NASD
Federal Tax Id: 223178468
Fax Number: 301.309.8512


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Monday, July 31, 2023